The association between irritable bowel syndrome and osteoporosis: a systematic review and meta-analysis

Wongtrakul, Wasit; Charoenngam, Nipith; Ungprasert, Patompong

doi:10.1007/s00198-020-05318-y

Cited by 12 publications

(16 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Critically, this study is in line with others in identifying vitamin D deficiency as widespread in IBS. There is recent, increasing recognition that IBS associates with increased risk of fracture[ 39 ] and of osteoporosis[ 40 ]. A causal inference is not yet possible, but poor vitamin D status in IBS may contribute to the observed association of these conditions.…”

Section: Discussionmentioning

confidence: 99%

Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial

Williams

Corfe

2021

Eur J Nutr

View full text Add to dashboard Cite

Purpose Several small trials suggest a benefit of vitamin D supplementation in irritable bowel syndrome (IBS). The generalisability of these reports is limited by their design and scale. This study aimed to assess whether vitamin D supplementation improved IBS symptoms in a UK community setting. Methods This was a randomised, double-blind, placebo-controlled study. Participants were recruited from the community in winter months between December 2017 and March 2019. 135 participants received either vitamin D (3,000 IU p.d.) or placebo for 12 weeks. The primary outcome measure was change in IBS symptom severity; secondary outcomes included change in IBS-related quality of life. Results The participants were analysed on an intent-to-treat basis. 60% of participants were vitamin D deficient or insufficient at baseline. Although vitamin D levels increased in the intervention arm relative to placebo (45.1 ± 32.88 nmol/L vs 3.1 ± 26.15 nmol/L; p < 0.001). There was no difference in the change of IBS symptom severity between the active and placebo trial arms (− 62.5 ± 91.57 vs – 75.2 ± 84.35, p = 0.426) over time. Similarly there was no difference between trial arms in τhe change in quality of life (− 7.7 ± 25.36 vs – 11.31 ± 25.02, p = 0.427). Conclusions There is no case for advocating use of vitamin D in the management of IBS symptoms. The prevalence of vitamin D insufficiency suggests routine screening and supplementation should be implemented in this population for general health reasons. This trial was retrospectively registered with ISRCTN (ISRCTN13277340) on 24th April 2018 after recruiting had been initiated.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial

Williams

Corfe

2021

Eur J Nutr

View full text Add to dashboard Cite

show abstract

“…There were 1.7 million hip fractures caused by osteoporosis in 2013 (Martin et al, 2020), and the number of such patients is expected to reach 6 million by 2050 (Kanis et al, 2001). The osteogenic effect of osteoblasts cannot balance osteoclast‐mediated bone resorption in osteoporosis patients, resulting in a gradual decrease in bone mass and bone density (Fu & Shi, 2020; Wongtrakul et al, 2020; Zeng et al, 2019). In addition to traditional antiresorptive agents (such as bisphosphonates) and hormone replacement therapy, anabolic agents are used either alone or in combination with antiresorptive agents to build new bone and reduce fracture risk, and several new drugs have been approved.…”

Section: Introductionmentioning

confidence: 99%

“…Previous research studies on osteoporosis have found that aging and apoptosis of BMSCs also contribute to the pathogenesis of osteoporosis (Shen et al, 2018). Aged BMSCs tend to differentiate into adipocytes rather than osteoblasts, thus inducing the age‐related bone loss (Wongtrakul et al, 2020). And the accumulation of ROS in cells caused by oxidative stress can cause stress‐induced precocious senescence and apoptosis of BMSCs (Xu et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Quercetin promotes osteogenic differentiation and antioxidant responses of mouse bone mesenchymal stem cells through activation of the AMPK/SIRT1 signaling pathway

Wang

Yang

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

Decrepitude and apoptosis of bone mesenchymal stem cells (BMSCs) induced by reactive oxygen species (ROS) lead to inhibited osteogenic differentiation, causing decreased bone density and osteoporosis. Quercetin, a bioactive component of Solanum muricatum extracts, promotes the osteogenic differentiation of BMSCs and ameliorates the symptoms of osteoporosis in vivo. However, the detailed mechanism underlying this process remains unclear. The study aims to reveal the regulatory mechanism of quercetin in BMSCs. Mouse BMSCs (mBMSCs) were isolated from the bone marrow and characterized by flow cytometry. QRT-PCR and western blot assays were performed to evaluate the expression levels of related genes and proteins. Alkaline phosphatase (ALP) staining and Oil Red O staining of lipids were used to estimate the osteogenesis and adipogenesis levels of mBMSCs, respectively. Quercetin treatment (2 and 5 μM) induced significant upregulation of antioxidant enzymes, SOD1 and SOD2, in mBMSCs. Quercetin promoted osteogenic differentiation and inhibited adipogenic differentiation of mBMSCs. Quercetin treatment enhanced the phosphorylation of AMPK protein and upregulated the expression of SIRT1, thus activating the AMPK/SIRT1 signaling pathway in mBMSCs. Quercetin promoted osteogenic differentiation and antioxidant responses of mBMSCs by activating the AMPK/SIRT1 signaling pathway.

show abstract

“…Recent studies have suggested that irritable bowel syndrome (IBS) could be a risk factor for osteoporosis, although the pathogenesis is still unknown. A meta-analysis of five studies investigated the risk of osteoporosis among patients with IBS, and the pooled analysis found that patients with IBS had a significantly higher risk of osteoporosis than individuals without IBS [ 1 ]. Chronic inflammatory conditions, hyperactivity of the hypothalamic pituitary adrenal gland, and nutritional deficiencies have all been implicated in a high risk of developing osteoporosis [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

The Risk of Osteoporosis and Osteoporotic Fracture Following the Use of Irritable Bowel Syndrome Medical Treatment: An Analysis Using the OMOP CDM Database

Kim

Hwang

et al. 2021

JCM

View full text Add to dashboard Cite

Patients with irritable bowel syndrome (IBS) are at increased risk of osteoporosis and osteoporotic fracture. This study investigated whether IBS medication attenuated the rate of osteoporosis and osteoporotic fracture risk. We conducted a retrospective large-scale multicenter study across eight hospital databases encoded in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The primary outcome was the incidence of osteoporosis, whereas secondary outcomes were osteoporotic fractures. After 1:4 matching, 24,723 IBS patients, 78,318 non-IBS patients, 427,640 non-IBS patients with IBS medication, and 827,954 non-IBS patients without IBS medication were selected. The risk of osteoporosis was significantly increased in the IBS group compared to the non-IBS group (hazard ratio (HR) 1.33; confidence interval (CI) 1.17~1.51). Even in patients who were not diagnosed with IBS, the risk of osteoporosis was significantly increased in those with IBS medication compared to those without (HR 1.77, CI 1.62~1.93). The risk of osteoporotic fracture was significantly increased in the IBS medication group (HR 1.69, CI 1.55~1.84). Patients exposed to IBS treatment even without IBS diagnosis were at increased risk of osteoporosis and osteoporotic fracture. Early diagnosis and treatment of osteoporosis should be considered in patients who have received medication for IBS symptoms.

show abstract

The association between irritable bowel syndrome and osteoporosis: a systematic review and meta-analysis

Cited by 12 publications

References 51 publications

Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial

Vitamin D supplementation in people with IBS has no effect on symptom severity and quality of life: results of a randomised controlled trial

Quercetin promotes osteogenic differentiation and antioxidant responses of mouse bone mesenchymal stem cells through activation of the AMPK/SIRT1 signaling pathway

The Risk of Osteoporosis and Osteoporotic Fracture Following the Use of Irritable Bowel Syndrome Medical Treatment: An Analysis Using the OMOP CDM Database

Contact Info

Product

Resources

About